NCT04035486: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
- State
- Under way
- Phase
- Phase 3
- People
- 587 taking part
- Started
- 2 Jul 2019
- Primary completion
- 3 Apr 2023
- Arms
- Osimertinib 80 mg QD and platinum-based chemotherapy
- Results
- Posted on the registry
- 2 Jul 2019: Trial started
- 29 Jul 2019: Trial registered
- 6 Aug 2024: Trial results posted